Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma
Author:
Affiliation:
1. Department of Hematology, Oncology and Rheumatology; Heidelberg University; Heidelberg Germany
2. Amyloidosis Center, Heidelberg University; Heidelberg Germany
3. National Center for Tumor Diseases, University Hospital; Heidelberg Germany
Funder
Sanofi
Publisher
Wiley
Subject
Cell Biology,Histology,Pathology and Forensic Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/cyto.b.21636/fullpdf
Reference32 articles.
1. The immunotherapy era of myeloma: Monoclonal antibodies, vaccines, and adoptive T-cell therapies;Hoyos;Blood,2016
2. Monoclonal antibodies in the treatment of multiple myeloma: Current status and future perspectives;Lonial;Leukemia,2016
3. Immunophenotyping in multiple myeloma and related plasma cell disorders;Kumar;Best Pract Res Clin Haematol,2010
4. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79;Lammerts van Bueren;Blood,2014
5. Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM);Lokhorst;J Clin Oncol,2014
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Selenium-based metabolic oligosaccharide engineering strategy for quantitative glycan detection;Nature Communications;2023-12-13
2. Molecular prediction of clinical response to anti‐PD ‐1/ anti‐PD‐L1 immune checkpoint inhibitors: New perspectives for precision medicine and mass spectrometry‐based investigations;International Journal of Cancer;2022-11-30
3. A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma;Hematological Oncology;2022-10-31
4. Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma;Scientific Reports;2022-06-29
5. Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement;PLOS ONE;2022-02-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3